Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): Impact of the new carbapenem breakpoints

Surgical Infections

Volumn 13, Issue 1, 2012, Pages 43-49

  Brink, Adrian J ^a   Botha, Roelof F ^b   Poswa, Xoliswa ^c   Senekal, Marthinus ^d   Badal, Robert E ^e   Grolman, David C ^f   Richards, Guy A ^f   Feldman, Charles ^f   Boffard, Kenneth D ^f   Veller, Martin ^f   Joubert, Ivan ^g   Pretorius, Jan ^h  

^a MILPARK HOSPITAL   (South Africa)

^b Ampath National Referral Laboratory   (South Africa)

^c Ampath Trust   (South Africa)

^d Pathcare Reference Laboratory   (South Africa)

^e Division of Microbiology   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFOTAXIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; AEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE FACULTATIVELY ANAEROBIC RODS; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEUS MIRABILIS; SOUTH AFRICA;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CILASTATIN; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; SOUTH AFRICA;

EID: 84858116778     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2011.074     Document Type: Article

References (26)

1. Chow JW, Satishchandran V, Snyder TA, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect 2005;6:439-448.
2. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-973. (Pubitemid 40883183)
3. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006;58:205-210. (Pubitemid 44295010)
4. Hawser SP, Bouchillon SK, Hoban DJ, et al. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum b-lactamases in community-and hospital-associated intra-abdominal infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010;54:3043-3046.
5. Hawser SP, Hoban DJ, Bouchillon SK, et al. Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis 2011;30:173-179.
6. Hawser SP, Bouchillon SK, Hoban DJ, et al. Epidemiologic trends, occurrence of extended-spectrum b-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the SMART Study. Surg Infect 2010;11:371-378.
7. Hoban DJ, Bouchillon SK, Hawser SP, et al. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: Data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diag Micro-biol Infect Dis 2010;66:78-86.
8. Hoban DJ, Bouchillon SK, Hawser SP, et al. Susceptibility of gram-negative pathogens isolated from complicated intra-abdominal infections in the United States 2007-2008: Results of the SMART Study. Antimicrob Agents Chemother 2010; 54:3031-3034.
9. Hawser SP, Badal RE, Bouchillon SK, et al., SMART India Working Group. Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008. J Med Microbiol 2010;59:1050-1054.
10. Hawser SP, Bouchillon SK, Hoban DJ, et al. Emergence of high levels of extended-spectrum b-lactamase-producing gram-negative bacilli in Asia/Pacific: Data from SMART 2007. Antimicrob Agents Chemother 2009;53:3280-3284.
11. Hsueh PR, Badal RE, Hawser SP, et al., 2008 Asia-Pacific SMART Group. Int J Antimicrob Agents 2010;36:408-414.
12. Yang Q, Wang H, Chen M, et al. Surveillance of antimicrobial susceptibility of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections in China: The 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2010; 36:507-512.
13. th ed. Document M07-A7. Wayne, PA. CLSI. 2006.
14. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. Twenty First Informational Supplement. Document M100-S21. Wayne, PA. CLSI. 2011.
15. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect 2010;11:79-109.
16. Elliott E, Brink AJ, van Greune J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum b-lactamase. Clin Infect Dis 2006;42:e95-e98.
17. Segal H, Elisha BG. Resistance to b-lactams, and reduced susceptibility to carbapenems, in clinical isolates of Klebsiella pneumoniae due to interplay between CTX-M 15 and altered outer membrane permeability. S Afr J Epidemiol Infect 2006; 21:41-44.
18. Feldman C, Ross S, Mahomed AG, et al. The aetiology of severe community-acquired pneumonia and its impact on initial empiric, antimicrobial chemotherapy. Respir Med 1995;89:187-192.
19. Paterson DL, Ko W-C, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum b-lactamase production in nosocomial infections. Ann Intern Med 2004;140:26-32. (Pubitemid 38055918)
20. Ko W-C, Paterson DL, Sagnimeni AJ, et al. Community-acquired Klebsiella pneumoniae bacteremia: Global differences in clinical patterns. Emerg Infect Dis 2002;8:160-166. (Pubitemid 34202438)
21. Brink AJ, Feldman C, Richards GA, et al. Emergence of extensive drug resistance (XDR) among gram-negative bacilli in South Africa looms nearer. South Afr Med J 2008;98: 586-592.
22. Fraser A, Paul M, Almanasreh N, et al., TREAT Study Group. Benefit of appropriate empirical antibiotic treatment: Thirty-day mortality and duration of hospital stay. Am J Med 2006;119:970-976. (Pubitemid 44634308)
23. Dupont H, Carbon C, Carlet J, The Severe Generalized Peritonitis Group. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an ami-noglycoside in treatment of severe generalized peritonitis: A multicenter randomized controlled trial. Antimicrob Agents Chemother 2000;44:2028-2033. (Pubitemid 30484422)
24. Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-489.
25. Pitout, JD, Nordmann P, Laupland KB, et al. Emergence of Enterobacteriaceae producing extended-spectrum b-lactamases (ESBLs) in the community. J Antimicrob Che-mother 2005;56:52-59. (Pubitemid 41418336)
26. Ben-Ami R, Rodriguez-Bano J, Arsian H, et al. A multinational survey of risk factors for infection with extended-spectrum b-lactamase-producing Enterobacteriaceae in non hospitalized patients. Clin Infect Dis 2009;49:682-690.